No thanks! I would like to know more about CHROMacademy

 Over 3000 E-Learning topics / 5000 Articles & Applications
 

The CHROMacademy Essential Guide Webcast:
Applying High Resolution and High Efficiency Size Exclusion Chromatography Technology to biotherapeutic Characterization

North America: Wednesday 15th May 2019,
8:00am PDT/ 11:00am EDT

Europe: Thursday 16th May 2019,
9:00am BST/ 10:00am CEST

Asia Pacific: Thursday 16th May 2019,
8:30am IST/ 11:00am CST/ 12:00pm JST



 
parker

Key Learning Objectives

Size Exclusion Chromatography (SEC) is considered a reference method for the qualitative and quantitative analysis of aggregates of proteins such as monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs).

Superior performance in high resolution, high efficiency, and high throughput analysis of mAbs, ADCs and fusion proteins can be achieved with Agilent’s new SEC column, with optimized sub 2 um particle and unique hydrophilic bonding chemistry.

Topics Covered

  • High-resolution, high-throughput aggregate and fragment analysis using a sub 2 micron SEC column
  • Biologics characterization using high efficiency size exclusion chromatography
  • Integrated SEC-MS analysis of monoclonal antibody (mAb) and antibody drug conjugates (ADCs) under native conditions
  • Tips and tricks for aggregate characterization method optimization

Presenters:
Veronica Qin, Ph.D., Agilent Technologies, Application Scientist
Yun Wang, Bristol-Myers Squibb, Research Scientist II
Zhengqi Zhang Ph.D., Frontage Laboratories, Inc., Scientist II 

Moderator:
Alasdair Matheson, Editor-in-Chief, LGCG Europe

Presenter Information »

 
 
loading data
loading data
loading data
loading data
loading data
Home | About UsContact Us | SubscribeTerms and Conditions | Advertise | Privacy Policy |

loading data

loading data

loading data

 

loading data


loading data

 

Veronica Qin, Ph.D., Agilent Technologies, Application Scientist


Veronica Qin is an application scientist for biocolumns and consumables at Agilent Technologies with in-depth knowledge and extensive hands-on experience of liquid chromatography and mass spectrometry for biotherapeutic characterization. Veronica obtained her PhD in chemistry with a focus on glycopolymer and glycoprotein based cancer vaccine development and characterization. Prior to join Agilent in 2017, Veronica worked as interns at Amgen, Pfizer and Biogen on protein biotherapeutic and oligonucleotide analysis.

Yun Wang, Bristol-Myers Squibb, Research Scientist II


Yun received her M.S. in Applied Chemistry from New Jersey Institute of Technology. Prior to joining BMS, Yun had been working in drug metabolism group at Roche for almost ten years. She designed and conducted biotransformation experiments in support of drug discovery and development projects. She is currently a Research Scientist II at BMS with the focus on mass spectrometry-based analytical strategies for biotherapeutics characterization.

Zhengqi Zhang Ph.D., Frontage Laboratories Inc., Scientist II


Zhengqi Zhang has extensive experience in liquid chromatography and mass spectrometry. He is currently working as a Scientist at Frontage Laboratories and is responsible for LC/MS methods development and validation for large molecules. Zhengqi graduated with a Master’s degree in Biotechnology and Enterprise from Exeter University in UK in 2011, and obtained his second Master’s degree in biochemistry from the University of Delaware in 2017. Zhengqi has built strong skills in LC/MS analysis, including intact mass, peptide mapping, glycan analysis and multiple reaction monitoring (MRM).